Jade Biosciences Inc (JBIO)

$12.48 -0.06 (-0.48%)
Market Cap 576.89M
Revenue (ttm) 0.00
Net Income (ttm) -69.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 136,000
Avg Vol 191,450
Day's Range N/A - N/A
Shares Out 46.00M
Stochastic %K 73%
Beta 1.07
Analysts Strong Sell
Price Target $19.80

Company Profile

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. It also develops JADE201 and JADE-003, which are in preclinical development stage. The company has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. was fo...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 312 3013
Address:
Building 23, Suite 105 221 Crescent Street, Waltham, United States
Quantumup
Quantumup Nov. 26 at 12:22 PM
Cantor reit'd $VERA Overweight-$100/said—We continue to view VERA shares as undervalued ($1.8B mkt cap with $497M cash as of Sep 30), given the competitive profile in lgAN, a multi-$B market that can easily accommodate multiple disease-modifying B cell modulators. $OTSKY $JBIO $ALNY $ABBV VRTX NVS IONS Cantor additionally said: This view is in line with that of multiple investors we spoke to at ASN who believe IgAN is a >$10B market for B-cell modulators. Our math suggests IgAN patients with proteinuria ≥0.5 g/day (76% according to literature (here)) represent 85K-151K US patients. Assuming annualized Tarpeyo pricing (~$180K), this subgroup alone could represent a market opportunity >$15B.
0 · Reply
JarvisFlow
JarvisFlow Nov. 25 at 12:28 PM
Clear Street has updated their rating for Jade Biosciences ( $JBIO ) to Buy with a price target of 25.
0 · Reply
Quantumup
Quantumup Nov. 25 at 11:57 AM
Clear Street🏁 $JBIO Buy/$25 $OTSKY $TVTX $NVS $VRTX IONS AZN CALT Clear Street said in its initiation report:
0 · Reply
CrispDry
CrispDry Nov. 21 at 7:04 PM
$JBIO what’s happening?
0 · Reply
Doozio
Doozio Nov. 21 at 5:30 PM
$JBIO Roger has a lot of room to run because it was always 🐒🍌🧠⏰♾️
0 · Reply
JarvisFlow
JarvisFlow Nov. 18 at 2:13 PM
Guggenheim has adjusted their stance on Jade Biosciences ( $JBIO ), setting the rating to Buy with a target price of 14 → 17.
0 · Reply
StockScanners
StockScanners Nov. 18 at 6:47 AM
$JBIO reached 13.57
0 · Reply
Michael_B_Jordan
Michael_B_Jordan Nov. 17 at 8:14 PM
My opinion on $JBIO for my fellow big investors out there, now looks like the cool down phase not the entry phase. you could get caught in a pull back or you will be exposed to unnecessary short term down side. wait for a cleaner dip or a confirmed break out before throwing in that huge buk 💸. follow for more, lets get it 💸💸💸
0 · Reply
EverX_Pivot88
EverX_Pivot88 Nov. 17 at 8:11 PM
$JBIO NXXT if i
0 · Reply
Taylor_Kinney
Taylor_Kinney Nov. 17 at 7:49 PM
$JBIO buyers are still active and confidence is intact. Who wants to make some money ? 💸
0 · Reply
Latest News on JBIO
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 4:05 PM EST - 13 days ago

Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

Nov 8, 2025, 11:00 AM EST - 18 days ago

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

Jade Biosciences to Participate in Upcoming Conferences

Nov 3, 2025, 7:00 AM EST - 23 days ago

Jade Biosciences to Participate in Upcoming Conferences

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

Oct 17, 2025, 4:05 PM EDT - 5 weeks ago

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

Oct 7, 2025, 7:05 AM EDT - 7 weeks ago

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

Jade Biosciences Announces $135 Million Private Placement

Oct 7, 2025, 7:00 AM EDT - 7 weeks ago

Jade Biosciences Announces $135 Million Private Placement

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Sep 2, 2025, 7:00 AM EDT - 3 months ago

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 3 months ago

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences to Participate in Two Upcoming Investor Conferences

Jul 8, 2025, 7:00 AM EDT - 5 months ago

Jade Biosciences to Participate in Two Upcoming Investor Conferences

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

Jul 1, 2025, 7:00 AM EDT - 5 months ago

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Jun 9, 2025, 7:00 AM EDT - 6 months ago

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

Jun 2, 2025, 7:00 AM EDT - 6 months ago

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 7 months ago

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 7 months ago

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

Quantumup
Quantumup Nov. 26 at 12:22 PM
Cantor reit'd $VERA Overweight-$100/said—We continue to view VERA shares as undervalued ($1.8B mkt cap with $497M cash as of Sep 30), given the competitive profile in lgAN, a multi-$B market that can easily accommodate multiple disease-modifying B cell modulators. $OTSKY $JBIO $ALNY $ABBV VRTX NVS IONS Cantor additionally said: This view is in line with that of multiple investors we spoke to at ASN who believe IgAN is a >$10B market for B-cell modulators. Our math suggests IgAN patients with proteinuria ≥0.5 g/day (76% according to literature (here)) represent 85K-151K US patients. Assuming annualized Tarpeyo pricing (~$180K), this subgroup alone could represent a market opportunity >$15B.
0 · Reply
JarvisFlow
JarvisFlow Nov. 25 at 12:28 PM
Clear Street has updated their rating for Jade Biosciences ( $JBIO ) to Buy with a price target of 25.
0 · Reply
Quantumup
Quantumup Nov. 25 at 11:57 AM
Clear Street🏁 $JBIO Buy/$25 $OTSKY $TVTX $NVS $VRTX IONS AZN CALT Clear Street said in its initiation report:
0 · Reply
CrispDry
CrispDry Nov. 21 at 7:04 PM
$JBIO what’s happening?
0 · Reply
Doozio
Doozio Nov. 21 at 5:30 PM
$JBIO Roger has a lot of room to run because it was always 🐒🍌🧠⏰♾️
0 · Reply
JarvisFlow
JarvisFlow Nov. 18 at 2:13 PM
Guggenheim has adjusted their stance on Jade Biosciences ( $JBIO ), setting the rating to Buy with a target price of 14 → 17.
0 · Reply
StockScanners
StockScanners Nov. 18 at 6:47 AM
$JBIO reached 13.57
0 · Reply
Michael_B_Jordan
Michael_B_Jordan Nov. 17 at 8:14 PM
My opinion on $JBIO for my fellow big investors out there, now looks like the cool down phase not the entry phase. you could get caught in a pull back or you will be exposed to unnecessary short term down side. wait for a cleaner dip or a confirmed break out before throwing in that huge buk 💸. follow for more, lets get it 💸💸💸
0 · Reply
EverX_Pivot88
EverX_Pivot88 Nov. 17 at 8:11 PM
$JBIO NXXT if i
0 · Reply
Taylor_Kinney
Taylor_Kinney Nov. 17 at 7:49 PM
$JBIO buyers are still active and confidence is intact. Who wants to make some money ? 💸
0 · Reply
topstockalerts
topstockalerts Nov. 17 at 7:39 PM
$JBIO buyers stepping in.. 🏦
0 · Reply
SwingTradesOnly
SwingTradesOnly Nov. 17 at 3:43 PM
$JBIO dat gap 👀
1 · Reply
StockScanners
StockScanners Nov. 15 at 4:14 AM
$JBIO keep watch if this holds above 10
0 · Reply
d_risk
d_risk Nov. 14 at 12:54 PM
$JBIO - Jade Biosciences, Inc. - 10Q - Updated Risk Factors JBIO’s risk factors now reflect its move to clinical stage, with heightened uncertainty around trial success, heavy reliance on JADE101, increased capital needs, global supply chain and enrollment challenges, expanded competition, shifting IP and regulatory risks, and new threats from cybersecurity, foreign expansion, and potential cash access issues. #Biotechnology #Cybersecurity #SupplyChain #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/JBIO/10-Q/2025-11-14
0 · Reply
Lol_at_ur_bags
Lol_at_ur_bags Nov. 12 at 5:48 PM
$CWD $JBIO $PTPI $XFOR Dude you’re hopping board to board glazing @invinc1ble. At least wipe the glizzy off before posting.
0 · Reply
DiegoModgill
DiegoModgill Nov. 6 at 3:18 AM
$JBIO - No one is watching this but soon!!
1 · Reply
DiegoModgill
DiegoModgill Oct. 25 at 1:42 AM
$JBIO BlackRock increased its position to 6.6% on this one, smart money is positioning for a parabolic run. Nov 7th
0 · Reply
DiegoModgill
DiegoModgill Oct. 21 at 8:22 AM
$JBIO - Rocket fuelling in - 7th Nov
0 · Reply
DiegoModgill
DiegoModgill Oct. 18 at 5:01 AM
$JBIO - This is one is Chosen
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 7 at 12:25 PM
$JBIO (+21.7% pre) Jade Biosciences unveils JADE201 antibody for autoimmune diseases https://ooc.bz/l/79520
0 · Reply
topstockalerts
topstockalerts Oct. 7 at 12:06 PM
$JBIO keep it on your radar..
0 · Reply